Product image of Haemate P (Human Coagulation Factor Viii, Human Von Willebrand Factor) supplied by GNH India

Haemate P

Active Ingredient:
Human Coagulation Factor Viii, Human Von Willebrand Factor
Origin:
EU

Haemate P (Human Coagulation Factor Viii, Human Von Willebrand Factor)

Haemate P is a prescription medication that contains human coagulation factor VIII and von Willebrand factor. It is supplied for intravenous administration and is used to replace deficient clotting proteins in patients with hemophilia A or von Willebrand disease. The product is marketed in the European Union and is classified as a coagulation factor replacement therapy.

Manufacturer / TM Owner

Csl Behring Gmbh

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Haemate P is indicated for the management of bleeding disorders related to factor VIII and von Willebrand factor deficiencies. It is used in both prophylactic and on‑demand treatment settings.

  • Treatment of acute bleeding episodes in hemophilia A patients.
  • Routine prophylaxis to prevent spontaneous bleeds in hemophilia A.
  • Management of bleeding episodes in von Willebrand disease.
  • Perioperative hemostatic support for surgical procedures in patients with these disorders.
  • Replacement therapy in patients with combined factor VIII and von Willebrand factor deficiency.

Side Effects

Side effects of Haemate P vary in frequency and severity. Patients should be monitored for any adverse reactions during and after infusion.

Common

  • Headache
  • Fever or chills
  • Nausea or vomiting
  • Injection site reactions such as redness or swelling
  • Mild hypertension
  • Transient increase in liver enzymes

Serious

  • Development of inhibitors (antibodies) against factor VIII
  • Anaphylactic or severe allergic reactions
  • Thromboembolic events (blood clots)
  • Severe hypertension or hypertensive crisis

Precautions & Warnings

Before using Haemate P, certain precautions should be considered to ensure safe administration.

  • Assess for a history of inhibitors to factor VIII or von Willebrand factor.
  • Monitor for signs of allergic reactions during infusion.
  • Use caution in patients with cardiovascular disease or a history of thrombosis.
  • Evaluate liver and renal function prior to initiating therapy.
  • Adjust dosing in pediatric patients based on weight and clinical response.
  • Ensure proper aseptic technique to prevent contamination of the intravenous line.

Avoid Interactions

Haemate P may interact with other medications that affect hemostasis or immune response.

Avoid

  • Concurrent use of other clotting factor concentrates without medical supervision.
  • High‑dose aspirin or non‑steroidal anti‑inflammatory drugs (NSAIDs) that increase bleeding risk.

Use with caution

  • Antifibrinolytic agents (e.g., tranexamic acid) when combined with factor replacement.
  • Immunosuppressive therapies that may alter inhibitor development.
  • Medications that affect blood pressure, such as vasoconstrictors.
  • Live vaccines, due to potential immune modulation.

Frequently Asked Questions

Haemate P provides human coagulation factor VIII and von Willebrand factor, restoring deficient clotting activity and supporting normal hemostasis in patients with hemophilia A or von Willebrand disease.

Haemate P is given by intravenous infusion under the supervision of a healthcare professional, typically in a clinical setting or at home after proper training.

Yes, Haemate P can be used as a regular prophylactic regimen to prevent spontaneous bleeds and also for on‑demand treatment of acute bleeding episodes.

Patients should be monitored for inhibitor development, allergic reactions, vital signs, and laboratory parameters such as liver enzymes and coagulation assays.

Haemate P can be used in children, with dosing adjusted based on body weight and clinical response, and under close medical supervision.

Common side effects include headache, fever, nausea, mild hypertension, and local infusion site reactions such as redness or swelling.

Serious reactions include the development of factor VIII inhibitors, severe allergic or anaphylactic responses, thromboembolic events, and hypertensive crises.

Antifibrinolytic agents may be used together with Haemate P, but this combination should be managed by a healthcare professional to balance hemostatic efficacy and safety.

Haemate P is contraindicated in patients with known hypersensitivity to any of its components or a history of severe inhibitor formation without appropriate medical guidance.

The product should be stored according to the manufacturer’s instructions, typically refrigerated, and protected from light until it is prepared for infusion.

Patients should contact their treating physician or hemophilia care team promptly to discuss the missed dose and receive guidance on the next steps.

Haemate P is currently marketed in the EU; availability in other regions depends on local regulatory approvals.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Human Coagulation Factor Viii, Human Von Willebrand Factor

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT